Treatment of acute uncomplicated influenza in patients who have had symptoms for 2 days or less.
Inhibits the enzyme neuraminidase, which may alter virus particle aggregation and release.
Reduced duration or prevention of flu-related symptoms.
Absorption: IV administration results in complete bioavailability.
Metabolism and Excretion: Mostly eliminated unchanged by kidneys (> 90%).
Half-life: 20.8 hr.
TIME/ACTION PROFILE (blood levels)
|IV||rapid||end of infusion||unknown|
Use Cautiously in:
- Renal impairment (dose ↓ required for CCr <50 mL/min)
- Geri: Consider age-related ↓ in hepatic, renal, cardiac function, concurrent diseases and drug therapy;
- OB: Use only if clearly needed
- Lactation: Consider benefits of breastfeeding, need for peramivir, and potential for adverse effects;
- Pedi: Safety and effectiveness not established.
Adverse Reactions/Side Effects
CNS: insomnia, neuropsychiatric events
Derm: ERYTHEMA MULTIFORME, STEVENS-JOHNSON SYNDROME
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Avoid use of live attenuated influenza vaccine within 2 wk prior and 48 hr after peramivir; interference may occur.
IV (Adults and Children) ≥13 yr) 600 mg x 1 dose.
IV (Children 2–12 yr) 12 mg/kg (max = 600 mg) x 1 dose.
IV (Adults and Children) ≥13 yr) CCr 30–49 mL/min–200 mg x 1 dose; CCr 10–29 mL/min–100 mg x 1 dose.
IV (Children 2–12 yr) CCr 30–49 mL/min–4 mg/kg (max = 600 mg) x 1 dose; CCr 10–29 mL/min–2 mg/kg (max = 600 mg) x 1 dose.
Solution for injection: 10 mg/mL
- Assess for signs and symptoms of influenza (fever, dyspnea, tachypnea, tachycardia, hypotension) prior to and at least daily during therapy. Patient must be symptomatic for no more than 2 days to receive peramivir.
- Monitor for signs of neuropsychiatric symptoms (hallucinations, delirium, abnormal behavior) during therapy.
- Assess patient for skin rash during therapy. Monitor closely and treat symptomatically.
Lab Test Considerations:
May cause ↑ serum ALT, AST, glucose, creatine kinase, and ↓ neutrophils.
- Risk for infection (Indications)
- Intermittent Infusion: Diluent: 0.9% NaCl or 0.45% NaCl, D5, or LR to a maximum volume of 100 mL. Solution is clear and colorless; do not administer solution that is discolored or contains a precipitate. Upon dilution, administer immediately or refrigerate up to 24 hrs; discard after 24 hrs. Allow to reach room temperature prior to administration. Discard unused portion of single use vial.
- Rate:Infuse over 15 to 30 min.
- Y-Site Incompatibility: Do not administer simultaneously with any other medication.
- Explain purpose of peramivir to patient.
- Advise patient to notify health care professional if signs and symptoms of anaphylaxis or rash, or neuropsychiatric symptoms occur.
- Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
Resolution of sign and symptoms of influenza.
The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Complete Product Information.